Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 May;14(5):529-34.
doi: 10.1046/j.1365-2036.2000.00739.x.

Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury

M T Donnelly  1 , A F Goddard, B Filipowicz, S V Morant, M J Shield, C J Hawkey
Affiliations
Clinical Trial

Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury

M T Donnelly et al. Aliment Pharmacol Ther. 2000 May.

Abstract

Introduction: The harmful effects of non-steroidal anti-inflammatory drugs (NSAIDs) on the gastric mucosa and the prophylactic effects of misoprostol are both dose-dependent.

Aim: To investigate whether a low-dose of misoprostol is sufficient to prevent gastric mucosal injury caused by low-dose aspirin.

Methods: We conducted a double-blind placebo controlled parallel group endoscopic study in 32 evaluable volunteers. The main outcome measure was erosive injury (ulcers and superficial erosions) in the gastric mucosa over 28 days.

Results: Most subjects developed erosions on aspirin 300 mg daily. This was significantly reduced by misoprostol 100 microg daily. (Odds ratio 0.18, 95% CI: 0.07-0.48). There were no drug-related or gastrointestinal adverse events in subjects receiving misoprostol.

Conclusion: Misoprostol 100 microg daily can prevent low-dose aspirin induced gastric mucosal injury without causing identifiable adverse effects.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources